Artificial intelligence tools based on large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, suggesting there is some way to go bef
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
